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Alterations in the expression of and response to growth factors is one of the biological
characteristics of tumors. In chapter 1, a review is presented regarding the reported
relations between p53 and growth factor regulation. The function of p53 tumor
suppressor protein is determined by various intrinsic properties of the protein. The effect
of p53 DNA-binding, and protein-protein i teractions are determined by the conformation
of the protein. Thus, p53 fulf i ls its role in cell cycle control and the onset of apoptotic ell
death, which can be altered when the wild-type p53 (M-p53) conformation is changed
after mutation.
The review focuses on the communal interactions of lt4- and mutant p53 (m-p53) with
growth factors and shows that m-p53 affects different ceil biological functions that
determine the malignant behaviour of cells. P53, for instance, can affect the response of
cells to groMh factors and growth factor-withdrawal. For interleukin-O (lL-6) signall ing it
has only recently become clear that p53 is able to inhibit the binding of STAT3 to DNA
(1). In this way mutant p53 could abrogate the normally lL-6-induceC differentiation of
cells and instead promote proliferation. This hypothesis was supported by the results of
Bell ido et al. (2) who showed that STAT3 protein are involved in the lL-6 induced
activation of the p21 (WAF1, ClPl) promoter. P21 plays a crucial role in cell
differentiation and especially STAT3 binding seems to be of importance.
Furthermore, p53 is involved in the expression of several growth factor- and groMh
factor receptor genes. These data suggest that restoration of the wild-type p53
phenotype in tumor cells can not only affect cell cycle control and apoptotic mechanisms
but also can reduce autocrine growth and restore sensitivity to physiological growth
inhibitors.
Autocrine production of cytokines is one of the biological features of human ovarian
carcinomas. Studies with cultured human ovarian tumor-derived cells and cell l ines have
elucidated some of the aspects of these autocrine growth mechanisms. In the chapters 2
and 4 of this thesis the expression of especially lL-O in this tumor type is described.
Human ovarian tumors have in over 50 % of the cases a mutated p53 gene. Since in
vlfro studies have shown a possible regulatory function of p53 protein in the expression
of growth factors such as lL-6, we questioned whether the expression of certain growih
factors in human ovarian tumors was associated with m-p53. In chapter 2, the relation
between p53 expression and cytokine expression is studied in human ovarian tumors. In
this study 30 tumors, obtained at diagnosis, are characterized tor p53 protein expression
with immunohistochemistry echniques and analyzed for the expression of macrophage
colony-stimulating factor (M-CSF), iL-6, lL-1R, lL-11, and tumor necrosis factor-cr (TNF-
cr) with Northern blotting. In accordance to earlier studies, nuclear as well as
cytoplasmatic p53 staining was observed in 27% of the tumors, whereas 30% showed
only cytoplasmatic staining, and 43 % showed no p53 staining. ln 70% of the cases M-
CSF mRNA was expressed, in 40% TNF-a, and in 30% lL-6. None of the tumors
expressed lL-18 or lL-11. The expression of TNF-c occurred more frequently in M-CSF
positive tumors compared to M-CSF negative ones. M-CSF expression was associated
with nuclear p53 staining. The p53 positive tumors expressed more frequently one or
more cytokines compared to p53 negative tumors. TNF-a expression was also
associated with response to chemotherapy.
This relatively small study suggests that mutations in the p53 gene might be associated
with cytokine overexpression in human ovarian carcinomas, especially the expression of
M-CSF mRNA.





































in chapter 3 and 4, the intracellular regulation of lL-6 gene expression in human ovarian
tumor cell l ines was further investigated. Until now, mechanisms of lL-6 expression and
regufation have been analyzed especially in haematopoietic cells and fibroblasts.
Therefore, two human ovarian cancer cell l ines, the 42780 and the CAOV-3, were
analyzed regarding transcription factor DNA-binding status and iL-6 promoter activity,
The cells were also exposed to TNF-a, since this factor was shown to be a potent
enhancer of lL-6 expression in various cell types.
CAOV-3 cells spontaneously secreted lL-6, which was enhanced by TNF-cr. The basic
lL-6 expression was associated with activator protein-1 (AP-1), and NF-lL6 DNA binding
as determined with electrophoretic mobil ity shift assay (EMSA). TNF-o also induced
nuclear factor kappa-B (NF-xB) which mainly consisted of p65-NF-xB. A2780 cells did
neither express lL-6 spontaneously nor after stimuiation with TNF-a. EMSAs, however,
showed AP-1 DNA binding. TNF-a stimulation enhanced AP-1 and induced NF-rB DNA
binding in these cells. No NF-|L6 DNA binding was observed spontaneously or after
TNF-cr treatment. NF-ILO protein, however, was detected in nuclear extracts of these
cells. Co-stimulation with interferon-y, a factor which in combination TNF-cr induced lL-6
expression in hematopoieic tumor cell l ines, induced lL-6 expression in 42780 cells
which was associated with increased NF-rB binding but not NF-lL6. This suggests that
NF-|L6 DNA binding is not necessary in lL-6 expression in this cell l ine and that other
pathways that also activate NF-rB are involved. lL-6 promoter transfection studies
showed no difference in promoter activation between CAOV-3 and 42780 that could
explain the fact that M780 cells do not express lL-6 after stimulation with TNF-cr. ln
addition, no mutations in the endogenous lL-6 enhancer of the 42780 cells were found.
This study reveals that differential lL-6 gene expression in two human ovarian cancer cell
l ines is not dependent on NF-|L6 activation. The signall ing pathways induced by TNF-a
and/or IFN-y are probably variable in these cells. NF-xB was most clearly activated in
both cell lines after TNF-cr and TNF-cr/lFN-v stimulation.
Several studies have indicated a role for p53 in the regulation of lL-6 expression.
Therefore, in chapter 4, the effect of p53 phenotypes that frequently occur in human
ovarian tumors, on the lL-6 promoter activation, was assessed. The human ovarian wt-
p53 cell line M780 was stably transfected with an empty plasmid (CMV) as control, or
plasmids expressing the mutant p53 fornrs, (m)-175-, m-248-, or m-273-p53. EMSAs
revealed a difference in AP-1 DNA-binding activity in the various clones. No differences
in NF-rB and NF-ILG were found. This is somewhat unexpected since earlier studies
revealed a role for NF-lL6 in the p53-affected lL-6 activation. Supershift analysis
demonstrated that the AP-1/DNA complexes in the various clones had variable compo-
sitions. Fra proteins were only present in AP-1 of the m-175 and m-248 clones. Since
differences in AP-1 composition could affect AF-1 DNA binding as well as transcriptional
activity, the lL-6 promoter activity was evaluated using intact and AP-1 binding site-
deleted constructs. Removal of the AP-'l site resulted in a decreased lL-6 promoter
activity in the CMV and m-273, and an increased activity in the m-175 clone, while no
change was observed in the m-248 clone. Exposure of the p53 clones to TNF-cr altered
distinguishly the AP-1/DNA complex composition whereas the lL-6 promoter activity was
enhanced by TNF-cr irrespective of the presence of an AP-1 binding site. The results
demonstrate that the basic and activated lL-6 promoter activity is differentially regulated
in the various p53 clones possibly due to alterations in the AP-1 composition. lt had been
noticed before that in fibroblasts, wt-p53 inhibited, whereas the p53val135 mutantform
stimulated the expression of the c-fos and c-jun promoters. lt has never been reported,
however, that the expression of other Fos and Jun family proteins or their participation in
the AP-'l/DNA consensus of the lL-6 promoter is under influence of p53.tos1,of l::1iy:s11{1^"39:i:r^^"_""Tll:::f ^l:,^iT:5,^"".i:":.::'^:T:l
regulator of solid tumors. Resistance, or loss of sensitivity, to TNF-u, can be associated 9l
with several mechanisms. One of the factors involved in resistance of tumor cells to
TNF-a, is the expression of c-erbB2. In chapter 5, the relationship between TNF-cr
sensitivity and doxorubicin-resistance of tumor cells was studied in a doxorubicin- @
resistant cell l ine panel consisting of the parental human small cell lung carcinoma cell 
,t
l ine GLCa plus GLCa-Adrzx and GLCa-Adr:so" with respectively doxorubicin resistance I
factors of 2 and 350 compared to GLCa. Previously, the cell l ines used in this study have +
been extensively examined and several mechanisms leading to doxorubicin-resistance o
have been identif ied. Compared to the parental cell l ine GLCr, the highly doxorubicin- ;
resistant GLCa-Adrgso" which is P-glycoprotein (P-Sp) negative has been shown to exhibit 6
an increased DNA-repair, increased detoxifying capacity, overexpression of the ?
multidrug resistant associated protein (MRP) and of the lung resistance protein (LRP). In ;
addition, GlCr-Adrsso' demonstrated ecreased topoisomerase-ll (Topo-ll) activity due z^
to decreased Topo-llcr and llB expression. At the highest dose of 1000 ng/ml TNF-a, 6
GLCa was almost completely resistant to TNF-o, whereas groMh inhibit ion was 2
observed in GLC+-Adrz, (37%) and GlCn-Adr3sox (68%). Sensitivity to TNF-a appeared to :
correlate inversely with the expression and gene copies of Topo-lla in these cell l ines. t
The gene encoding for c-erbB2 is in the proximity of the Topo-llo gene and its product is I
known to be one of the mechanisms of resistance to TNF-a. The doxorubicin-resistant 3
cell l ines with decreased Topo-lla gene copies have a simultaneous decrease in c-erbB2 a
gene copies, probably due to l inkage between these two genes. The reduced number of
c-erbB2 gene copies coirrcided with decreased c-erbB2 expression and subsequently in
increased sensitivity to TNF-cr..
Additionally, it was analyzed whether other mechanisms were associated with TNF-
resistance in GLCq. There was no difference in TNF receptor-1 expression between the
cell lines. Compared to the TNF-sensitive GLCr-Adr:s0", GLCq appeared to have a
decreased activation of NF-xB after exposure to TNF-cr which might indicate a reduced
TNF-receptor function. In GLC+ increased Bcl-2 expression was found, a protein
described to confer TNF-cr resistance. Moreover, it was demonstrated that combining
TNF-o with the apoptosis associated poly ADP-ribose polymerase inhibitors 6-
aminonicotinamide and 3-aminobenzamide did not affect TNF-a sensitivity in GLCo and
GLCr-Adrgso,, excluding a pivotal role of poly ADP-ribose polymerase in TNF-s
resistance in these cell l ines.
These data show that doxorubicin-resistant tumor cell l ines with decreased Topo-llo
gene copies can become sensitive to TNF-u probably due to loss of c-erbB2 gene
copies. Furthermore, we found that several mechanisms associated with c-erbB2
overexpressing contribute to TNF-cr esistance in GLC+.
Multidrug resistance is the phenomenon that tumor cells are resistant to a group of
natural drugs such as, anthracyclines, vinca-alkaloids, and epidophyllotoxins. Several
mechanisms involved in multidrug resistance have been identif ied of which overex-
pression of P-glycoprotein, and multidrug resistance-related protein-1 account for
increased drug efflux. Another mechanism of multidrug resistance is a decrease in the
drug target Topo-ll. ln an attempt o overconre multidrug resistance, several modulators
have been explored, among which the P-gp blockers, verapamil, cyclosporin A, and PSC
833. Several growth factors have shown to be potent proliferation stimulators of
malignant hematopoietic ells. Furthermore, colony stimulating factors were shown to
stimulate proliferation and to upregulate the expression of Topo-ll and sensitize
malignant blasts to chemotherapeutic drugs. In chapter 6, a growth factor-dependent
erythroid leukemic ell l ine TF-1 was treated with lL-3 in order to attempt o modulate its
sensitivity to etoposide, a chemotherapeutic agent frequently used in the treatment of














when TF-1 cells were pre-incubated for 24 hours with lL-3 followed by t hour of
treatment with etoposide. The increased cell death could not be ascribred to an increased
number of apoptotic cells. The lL-3 treatment coincided with an upregulation of DNA
Topo-llo at mRNA and protein level after 24 hours, which was preceded by an
upregulation of the oncogenic -myc mRNA. In contrast, Topo-llR did not demonstrate an
upregulation at mRNA level in response to lL-3. In addition it was shown that the
increase in Topo-lla resulted in a higher number of cleavable DNA complexes in cells
treated with lL-3 followed by etoposide. This was not due to an increased etoposide
uptake, since intracellular etoposide concentrations were not affected by lL-3. These
data indicate that lL-3 modulates the etoposide cytotoxicity by upregulation of the
etoposide target Topo-llcr in TF-1 cells.
In chapter 7, the concept of growth factor-modulated drug cytotoxicity was further
explored. The study combines the administration of lL-3 and the P-gp blocker PSC 883
in order to modulate the cytotoxic effects of mitoxantrone and daunorubicin on two P-gp
positive myeloid leukemic cell l ines Mo-7 and GF-D8. Increased cytotoxicity occurred in
Mo-7 cells pre-incubated for 24 hours with lL-3 followed by mitoxantrone or
daunorubicin. Similar results were obtained for the GF-D8 cell l ine. The lL-3 admi-
nistration did not affect P-gp and the apoptosis-inhibitor bcl-2 protein expression, cellular
mitoxantrone concentration or mitoxantrone ff lux. lt did, however, coincide with an
increase in the % of cells in S phase and Topo-ilo, mRNA and Topo-ll activity especially
in the Mo-7 cell l ine. PSC 833 enhanced daunorubicin cytotoxicity in both cell l ines. The
combined administration of lL-3 and PSC 833 in the Mo-7 cell l ine resulted in an additive
effect on daunorubicin cytotoxicity. The additive effect of lL-3 and PSC 833 was most
pronounced in GF-D8 cells, which had also the highest P-gp expression. In contrast PSC
833 did not modulate the mitoxanti'one ffects, irrespective of the presence of lL-3. In
summary the results demonstrate that the combined administration of lL-3 and PSC 833
did enhance the cytotoxic effects of daunorubicin but not mitcxantrone in two P-gp
positive cell lines whereas the effects of mitoxantrone could be modulated by factors that
influence Topo-ll activity.
Perspectives
In this thesis three growth factor associated phenomena, expression of the autocrine
growth factor lL-6 in human ovarian carcinoma, resistance to the growth suppressing
activity of TNF-o, and growth factor-modulated rug resistance in acute myeloid
leukemia re described.
Human ovarian tumors that express TNF-a show a better response to cisplatin-
containing chemotherapy. Understanding the mechanisms underlying lL-6 expression in
human ovarian tumor cells, might in the future, hand points for intervention, for example,
by decreasing autocrine lL-6 secretion. Since NF-xB was found to be an important factor
in the regulation of lL-6 expression in human ovarian cancer cell l ines, down-regulation
of the nuclear NF-xB expression with groMh factors or antisense p-65 might be of
potential interest. In addition it is potentially useful to restore the wt-p53 phenotype by
transfection of wt-p53 or by m-p53 anti-sense therapy. In this way, not only autocrine
pathways could be affected but the programmed cell death pathways could also be
restored which might increase the sensitivity of tumor cells to chemotherapy. Currently,
clinical studies with p53 gene therapy, also in ovarian carcinoma, are ongoing.
Suppression of endogenous lL-6 expression by, for instance, antisense oligonucleotides
might be feasible, but has not yet been assessed. In cell l ine and animal models,
antisense strategies, directed to other growth factor and their receptors are explored.
Examples are antisense strategies directed at insulin-l ike growth factor I and l l and its
receptor in ovarian cancer cells (3, 4), vascular endothelial growth factor in melanoma
cells (5), HER2ineu in breast carcinoma cells (6), and epidermal growur rd\.ru, o,,v
receptor in head and neck squamous cell carcinoma (7), renal cell cancer (8), and colon
carcinoma (9, 10).
We showed that various p53 transfectants in the human ovarian 12780 cell line display
AP-1/DNA complexes with different Fos and Jun family proteins. lt is still unclear how
p53 precisely affects the AP-1 composition. Further analysis might reveal whether these
differences are due to altered gene expression or phosphorylation of the subunits.
Combination therapy of TNF-o with melphalan in isolated limb perfusion demonstrated
distinct anti-tumor effects (11,12). To hit various targets instead of just one is explored
more and more in anti-cancer treatment. This idea was also tested in vitro, in order to
circumvent multidrug resistance with growth factors and P-gp inhibitors.
The application of lL-3 and other growth factors have been shown useful to increase
sensitivity of acute myeloid leukemic cell lines to various chemotherapeutic drugs in vitro.
We and others have observed that the increased response induced by growth factors
was associated with an increased number of cells in S phase and higher Topo-ll mRNA
and protein levels. Additional studies should reveal whether this approach is useful in the
clinic and whether a combination of groMh factors added to MDR-related
chemotherapeutic drugs would be more effective in the circumvention of multidrug
resistance. Co-administration of lL-1 and lL-3 could induce proliferation of the
heterogeneous population of early and more committed acute myeloid leukemia blasts ln
vlvo. Furthermore, besides TNF-u and the hematopoietic growth factors, lL-6 and lL-1
might afso be applied in vivo to sensitize solid tumor cells, such as ovarian tumor cells, to
Topo-ll directed drugs. Intensive studies could reveal additional mechanisms and keys to
improve the use of growth factors in anti-cancer therapies.
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